# US 6,727,254 B2 · Heteroaryl tropane derivatives as superior ligands for nociceptin receptor ORL-1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,727,254 B2
- Document ID: US6727254B2
- Status: Granted
- Kind: B2
- Application number: 10/288,976
- Filed: 2002-11-06
- Published: 2003-06-26
- Granted: 2004-04-27
- Earliest claimed: 2001-11-07
- Assignees: Schering Corporation
- Inventors: Deen Tulshian; Ginny D. Ho; Fay W. Ng
- Web page: https://patentgrep.com/patent/US6727254B2

## CPC

- C07D 451/06: Oxygen atoms
- A61P 11/06: Antiasthmatics
- A61P 11/10: Expectorants
- A61P 11/14: Antitussive agents
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/32: Alcohol-abuse
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Novel compounds of the formula wherein R is optionally substituted heteroaryl or R1 is H or C1-C6 alkyl; and R2 and R3 are —CH3, —OCH3 or halo; or a pharmaceutically acceptable salt or solvate thereof, pharmaceutical compositions therefore, and the use of said compounds in the treatment of pain, anxiety, cough, asthma, depression and alcohol abuse are disclosed.

## Claims

### Claim 1

A compound represented by the formula
or pharmaceutically acceptable salts thereof, wherein
R is R4-heteroaryl or
R1 is H or C1-C6 alkyl;
R2 and R3 are independently selected from the group consisting of —CH3, —OCH3, fluoro, chloro, bromo and iodo;
R4 is 1 to 4 substituents independently selected from the group consisting of H, halo, (C1-C6) alkyl, —CN, —CF3, —OCF3, —(CH2)n—OR5, —(CH2)n—NR5R6, —(CH2)n—NHSO2 R5, —(CH2)n—NH(CH2)2NR5R6, —(CH2)n—NHC(O)NR5R7, —(CH2)n—NH(CH2)2OR5 and 1-piperazinyl;
n is 0, 1, 2 or 3;
R5 and R6 are independently selected from the group consisting of H and C1-C-3 alkyl; and
R7 is H, C1-C-3 alkyl or amino(C1-C-3)alkyl.

### Claim 2 (depends on 1)

A compound of claim 1 wherein R is R4-pyrimidinyl or R4-pyridyl.

### Claim 3 (depends on 2)

A compound of claim 2 wherein R is 2-pyridyl or 2-pyrimidinyl.

### Claim 4 (depends on 2)

A compound of claim 2 wherein R4 is selected from the group consisting of (C1-C6) alkyl, —OR5 and 1-piperazinyl.

### Claim 5 (depends on 2)

A compound of claim 2 wherein R is 2-pyrimidinyl, 5-ethyl-2 pyrimidnyl, 4-(1-piperazinyl)-2-pyrimidinyl, 2-pyridyl or 6-methoxy-2-pyridyl.

### Claim 6 (depends on 1)

A compound of claim 1 wherein R1 is H or —CH3.

### Claim 7 (depends on 1)

A compound of claim 1 wherein R2 and R3 are in the 2-position on the phenyl rings.

### Claim 8 (depends on 7)

A compound of claim 7 wherein R2 is 2-chloro and R3 is 2-chloro.

### Claim 9 (depends on 1)

A compound of claim 1 selected from the group consisting of

### Claim 10

A compound represented by the formula:

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 in combination with a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising: a therapeutically effective amount of at least one compound of claim 1; a therapeutically effective amount of one or more additional agents selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors, leukotriene inhibitors, H3 inhibitors, β-adrenergic receptor agonists, xanthine derivatives, α-adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, NK1, NK2 and NK3 tachykinin receptor antagonists, and GABAB agonists; and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 1)

A method of treating cough, pain, anxiety, asthma, depression or alcohol abuse comprising administering an effective amount of at least one compound of claim 1 to a mammal in need of such treatment.

### Claim 14 (depends on 1)

A method of treating cough comprising administering an effective amount of at least one compound of claim 1 to a mammal in need of such treatment.

### Claim 15 (depends on 1, 14)

The method of claim 14, wherein in addition to the compound of claim 1, an effective amount of 1-3 additional agents for treating cough, allergy or asthma symptom selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors, leukotriene inhibitors, H3 inhibitors, β-adrenergic receptor agonists, xanthine derivatives, α-adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorants, NK1, NK2 and NK3 tachykinin receptor antagonists, and GABAB agonists is administered.

### Claim 16 (depends on 10)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 10 in combination with a pharmaceutically acceptable carrier.

### Claim 17 (depends on 10)

A pharmaceutical composition comprising: a therapeutically effective amount of the compound of claim 10; a therapeutically effective amount of one or more aditional agents selected from the group consisting of: antihistamines 5-lipoxygenase inhibitors, leukotriene inhibitors, H3 inhibitors, β-adrenergic receptor agonists, xanthine derivatives, α-adrenergic receptors, mast cell stabilizers, anti-tussives, expectorants, NK1, NK2 and NK3 tachykinin receptor antagonists, and GAGAB agonists; and a pharmaceutically acceptable carrier.

### Claim 18 (depends on 10)

A method of treating cough, pain, anxiety, asthma, depression or alcohol abuse comprising administering an effective amount of the compound of claim 10 to a mammal in need of such treatment.

### Claim 19 (depends on 10)

A method of treating cough comprising administering an effective amount of the compound of claim 10 to a mammal in need of such treatment.

### Claim 20 (depends on 10, 19)

The method of claim 19, wherein in addition to the compound of claim 10, an effective amount of 1-3 additional agents for treating cough, allergy or asthma symptoms selected from the group consisting of: antihistamines, 5-lipoxygenase inhibitors, leukotriene inhibitors, H3 inhibitors, β- adrenergic receptor agonists, xanthine derivatives, α-adrenergic receptor agonists, mast cell stabilizers, anti-tussives, expectorents, NK1, NK2 and NK3 tachykinin receptor antagonists, and GABAB agonists is adminstered.
